Skip to main content
. 2021 Nov 20;26(22):7021. doi: 10.3390/molecules26227021

Figure 5.

Figure 5

The tumor level of the malondialdehyde (MDA) and nitric oxide (NO) in EST-suffering mice treated with 10-HDA alone and in combination with cyclophosphamide (CP). Non-EST and non-treated mice (C1); EST mice receiving the normal saline (C2); EST mice treated with CP (50 mg/kg) intraperitoneally once a day for 3 days (C3); EST mice treated with 10-HDA 2.5 mg/kg orally once a day for 2 weeks (E1); EST mice treated with 10-HDA 5 mg/kg orally once a day for 2 weeks (E2); EST mice treated with 10-HDA 2.5 mg/kg + CP (25 mg/kg) once a day for 2 weeks (E3); EST mice treated with 10-HDA 5 mg/kg + CP (25 mg/kg) once a day for 2 weeks (E3). Data are expressed as the mean ± SD (n = 3). * p < 0.001 significant difference compared with C2 group; + p < 0.001 significant difference compared with C3 group.